|Videos|August 2, 2021
Roundtable: Synthetic Control Arms and Regulatory/HTA Requirements
Author(s)Parexel
Advertisement
A roundtable discussing the opportunities that synthetic control arms offer for patients and product developers, and how to overcome potential barriers with the use of this burgeoning clinical trial model.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX
2
FDA Continues to Expand National Priority Voucher Program
3
FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma
4
Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?
5
